Skip to Content
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 04/22/22

Information below provided by the Pharmaceutical Company.

Capivasertib (AZD5363)

Agent Description

Capivasertib is a potent, selective inhibitor of the kinase activity of serine/threonine specific protein kinase (AKT) and is being developed as a potential treatment for solid and hematological malignancies. Capivasertib is currently in Phase 2 of development.

Mechanism of Action

AKT inhibition


serine/threonine kinase (AKT) inhibitor

Molecular Targets

AKT 1, 2 and 3


Capivasertib clinical program is assessing the clinical utility of the agent in combination with anti-hormonals (breast and prostate), as well as chemotherapy combinations in a variety of tumor types. These approaches are complimented by a targeted population approach looking at patient segments with activating mutations of the PI3K pathway.

Studies of Interest

Proposals for agent supply support only

Information collaborator would like included in investigator proposals